Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pivalopril is a new orally active inhibitor of angiotensin-converting enzyme.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
In vivo | Pivalopril, a novel compound featuring a hindered sulfur group, exhibits promising properties as an orally effective angiotensin-converting enzyme (ACE) inhibitor and antihypertensive agent, showcasing superior effects compared to Captopril in various studies. When administered to conscious normotensive dogs and spontaneously hypertensive rats (SHR), Pivalopril demonstrates dose-related antagonism of angiotensin I (AngI) pressor effects and a notable reduction in mean arterial pressure, highlighting its potency and effectiveness at incremental doses ranging from 0.01-1.0 mg/kg orally. Notably, when dosed at 100 mg/kg per day, Pivalopril outperforms Captopril in lowering mean arterial pressure. The ED50 values for Pivalopril and Captopril further affirm its competitive efficacy in both dogs and rats. Furthermore, Pivalopril shows a similar duration of action to Captopril at equieffective doses, underscoring its potential as a potent antihypertensive treatment option. |
別名 | Pivopril, RHC 3659(S) |
分子量 | 329.45 |
分子式 | C16H27NO4S |
CAS No. | 81045-50-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pivalopril 81045-50-3 Endocrinology/Hormones RAAS RHC3659 RHC-3659 Pivopril RHC 3659 RHC 3659(S) Inhibitor inhibitor inhibit